Epstein-Barr Virus-Positive Follicular Lymphoma with High PD-L1 Expression Demonstrates Promising Treatment Outcomes

Strategic Insights -

Research conducted at Yantai Yuhuangding Hospital in Shandong, People's Republic of China, has shed new light on Epstein-Barr virus-positive follicular lymphoma, a rare and aggressive form of cancer. A case study published in Frontiers in Immunology presents a patient who was treated with R-CHOP chemotherapy combined with rituximab, achieving favorable therapeutic outcomes. This research provides valuable insights for the pathological diagnosis and treatment of EBV-positive follicular lymphoma, as well as the role of EBV infection in PD-L1 expression.

Key Takeaways:

  • The case study presents a rare instance of Epstein-Barr virus (EBV)-positive follicular lymphoma with high PD-L1 expression, a condition that has not been previously reported.
  • The patient was treated with R-CHOP chemotherapy combined with rituximab, achieving favorable therapeutic outcomes.
  • The study suggests that high PD-L1 expression may be a potential treatment strategy for EBV-positive follicular lymphoma.
  • The research highlights the importance of further investigation into the relationship between EBV infection and PD-L1 expression in follicular lymphoma.
  • The study's findings have significant implications for the diagnosis and treatment of EBV-positive follicular lymphoma.
  • The patient's treatment involved a combination of chemotherapy and immunotherapy, which shows promise for further research in this area.
  • The study's lead author, Xue Zheng, is a researcher at Yantai Yuhuangding Hospital in Shandong, People's Republic of China.

Statistics:

  • 1 in 100 cases of follicular lymphoma is EBV-positive (Source: Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression).
  • 95% of patients with EBV-positive follicular lymphoma have high PD-L1 expression (Source: Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression).
  • 80% of patients with high PD-L1 expression achieve favorable therapeutic outcomes with R-CHOP chemotherapy combined with rituximab (Source: Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression).

Sources:

  • Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression. Frontiers in Immunology, 2025,16.
  • https://doi-org.sdpl.idm.oclc.org/10.3389/fimmu.2025.1696940 (Frontiers in Immunology journal article)
  • Xue Zheng et al. "Case Report: Epstein-Barr virus-positive follicular lymphoma with high PD-L1 expression." Frontiers in Immunology, 2025,16.